Phaseline

Companies › BioCardia

BioCardia: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem
Allogenic bone marrow-derived mesenchymal stem cells with immunomodulatory and regenerativ
–Phase 1Heart Failure, SystolicDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05925608CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal StemPhase 1Heart Failure, SystolicCardiovascularDec 2026

From the company's SEC filings

Cash of $4m on 2026-06-30; operating cash outflow about $7m a year; runway about 7 months at that burn, to Feb 2027

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.